Influenza viruses are a moving target, forcing drug developers to modify their products annually based on the strains most likely to dominate a given season. SARS-CoV-2 could follow a similar trajectory in the first few years of the pandemic, according to a study published in Virus Evolution. SARS-CoV-2 is likely to continue to accumulate changes…